ACC.23 In a multisite-RCT study was examined whether an intervention including individualized reminders sent to primary care clinicians improved use of high-intensity statin in patients with ASCVD.

ACC.23 Injectable treatments may have poor adoption due to access barriers and the need for repeat injections. An oral PCSK9 inhibitor, MK-0616, was developed and tested in a phase 2b trial.

ACC.23 The CLEAR Outcomes study showed that among statin-intolerant primary and secondary prevention patients, bempedoic acid reduced the risk of the primary composite endpoint of nonfatal MI, nonfatal stroke, coronary revascularization or CV death.

A Dutch cross-sectional study showed that Lp(a) levels were higher and more often elevated in children with a clinical presentation of FH in whom no FH-causing mutation was detected compared with children with a mutation and their unaffected siblings.

In an ORION-11 substudy, inclisiran reduced LDL-c, non-HDL-c and apoB levels in a subgroup of high-risk patients with elevated LDL-c but without prior CV events receiving maximally tolerated statin therapy.

AHA 2022 In individuals with an increased 10-year ASCVD risk, rosuvastatin 5 mg daily reduced LDL-c, TC, and TG more than fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice, or placebo. Moreover, no supplements reduced LDL-c significantly compared with placebo.

In an RCT with 71 participants, low-frequency intermittent fasting for 26 weeks did not alter LDL-c levels compared with an ad libitum diet. However, it did lower insulin resistance and the metabolic syndrome score.

The HAUSER-RCT study showed that in pediatric patients with HeFH, treatment with evolocumab for 24 weeks is safe and reduces LDL-c levels, compared with placebo. But what about the long-term safety and efficacy of evolocumab in this patient population?

In a population-based cohort study, the clinical performance of the 2021 ESC Guidelines for CVD prevention on eligibility of primary prevention with statins was compared with that of the 2019 ESC/EAS, 2016 NICE, and 2013 ACC/AHA guidelines.

ESC 2022 ‘There is a lot of misinformation about how dangerous statins are’ says Prof. Baigent. This analysis showed that there is a small excess of muscle symptoms in the first year after starting statin therapy, but no excess in risk thereafter.

ESC 2022 In the open-label extension of the FOURIER trial, evolocumab maintained LDL-c reduction. Moreover, early treatment initiation was associated with sustained accumulation of CV benefit, including CV death.

ESC 2022 The researchers of this meta-analysis aimed to provide reliable information about the effects of statins on muscle adverse events from double-blind, randomized trials.